LIF anticorps (AA 101-202)

N° du produit ABIN737046

Détail du produit anti-LIF anticorps

Antigène: LIF (Leukemia Inhibitory Factor (LIF))

Épitope: AA 101-202

Reactivité: Humain, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp LIF est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Réactivité croisée: Humain, Souris

Homologie: Rat,Dog,Cow,Pig,Rabbit

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human LIF

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Références pour anticorps anti-LIF (ABIN737046)

Liang, Zhou, Jiang, Zhang, Wang, Wang: "Expression of LIF and LIFR in periodontal tissue during orthodontic tooth movement." dans: The Angle orthodontist, Vol. 81, Issue 4, pp. 600-8, (2011) (PubMed).

Détails sur LIF

Antigène: LIF (Leukemia Inhibitory Factor (LIF))

Autre désignation: LIF (LIF Produits)

Synonymes: anticorps CDF, anticorps DIA, anticorps HILDA, anticorps MLPLI, anticorps LIF, interleukin 6 family cytokine, anticorps leukemia inhibitory factor, anticorps LIF, anticorps Lif

Sujet:

Synonyms: CDF, DIA, HILDA, MLPLI, Leukemia inhibitory factor, LIF, Differentiation-stimulating factor, D factor, Melanoma-derived LPL inhibitor

Background: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.

ID gène: 3976

UniProt: P15018

Pathways: Signalistation JAK/STAT, Positive Regulation of Peptide Hormone Secretion, Negative Regulation of Hormone Secretion, Stem Cell Maintenance, Growth Factor Binding